secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001185185-23-000238
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

India Globalization Capital rebrands as IGC Pharma, effective March 30, 2023
----------------------------------------------------------------------------

- Name change to IGC Pharma, Inc. effective March 30, 2023; ticker symbol IGC unchanged.
- Company highlights focus on THC-based drug IGC-AD1 in Phase 2 trials for Alzheimer's agitation.
- IGC-AD1 is the only natural, THC-based investigational drug in FDA trials for Alzheimer's.
- Wellness brand Holief targets premenstrual syndrome, menstrual cramps, and sleep disorders.
- CEO Ram Mukunda states rebranding aligns name with strategic pharma focus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518523000238/0001185185-23-000238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518523000238/indiaglob20230318_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-23-000238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer